Skip to main content

PXN KO cell line available to order. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9; X = 7 bp deletion, 1 bp insertion; Frameshift = 99.7%.

Be the first to review this product! Submit a review

Images

Western blot - Human PXN (Paxillin) knockout A-431 cell line (AB261892), expandable thumbnail
  • Western blot - Human PXN (Paxillin) knockout A-431 cell line (AB261892), expandable thumbnail
  • Western blot - Human PXN (Paxillin) knockout A-431 cell line (AB261892), expandable thumbnail
  • Next Generation Sequencing - Human PXN (Paxillin) knockout A-431 cell line (AB261892), expandable thumbnail
  • Next Generation Sequencing - Human PXN (Paxillin) knockout A-431 cell line (AB261892), expandable thumbnail

Key facts

Cell type
A-431
Species or organism
Human
Tissue
Skin
Form
Liquid
Knockout validation
Next Generation Sequencing, Western blot
Mutation description
Knockout achieved by CRISPR/Cas9; X = 7 bp deletion, 1 bp insertion; Frameshift = 99.7%

Alternative names

FLJ16691, FLJ23042, PAXI_HUMAN, PXN, PXN protein, Paired box protein Pax 1, Paxillin, Paxillin alpha

Recommended products

PXN KO cell line available to order. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9; X = 7 bp deletion, 1 bp insertion; Frameshift = 99.7%.

Key facts

Cell type
A-431
Form
Liquid
Mutation description
Knockout achieved by CRISPR/Cas9; X = 7 bp deletion, 1 bp insertion; Frameshift = 99.7%
Disease
Epidermoid Carcinoma
Concentration
Loading...

Properties

Gene name
PXN
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing, Western blot

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 1 US: 1
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type A-431 cell line (ab263975). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

Paxillin also known as PXN is a cytoskeletal protein involved in the assembly of focal adhesions. It has a molecular weight of approximately 68 kDa. You will find Paxillin expressed widely in various tissues including the liver colon and lung. Paxillin plays a part in cell motility by interacting with other focal adhesion proteins. It plays a significant mechanical role by serving as a docking site for structural and signaling molecules.

Biological function summary

Paxillin serves key functions in cellular processes such as migration proliferation and survival. It interacts with different proteins including vinculin and talin forming part of a complex at the focal adhesion sites. The phosphorylation state of Paxillin can modulate its interactions and in this way influence the assembly of signaling complexes that control dynamic cellular processes.

Pathways

Paxillin participates in the integrin signaling and MAPK pathways. It operates by linking integrin receptors to the actin cytoskeleton facilitating signal transduction. Paxillin phosphorylation is an important regulatory mechanism within these pathways. In particular its interaction with focal adhesion kinase (FAK) and Src family kinases signifies its role in transmitting signals from the extracellular matrix to the cellular interior which impacts cell behavior and response.

Associated diseases and disorders

Paxillin has links with osteosarcoma and lung cancer. Deregulation of Paxillin expression or its phosphorylation state contributes to oncogenic transformation and tumor progression. In cancer Paxillin associates with altered activity of proteins such as Src and FAK exacerbating disease states. This relationship highlights Paxillin's potential as a biomarker and therapeutic target in treating related malignancies.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

6 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com